BioDirection®, Inc. Closes $18 Million Series C Financing Led by Shepherd Kaplan Krochuk, LLC
Jul 01, 2020•about 5 years ago
Amount Raised
$18 Million
Round Type
series c
Description
BioDirection®, Inc. d/b/a NanoDiagnosticsTM, Inc. (NanoDxTM), a privately held medical device company developing cutting-edge and rapid point-of-care in-vitro diagnostic products for the objective detection, diagnosis and management of Traumatic Brain Injury (TBI), virus detection and inflammatory disease today announced that it has closed an $18 million Series C Convertible Preferred Stock Financing. The financing was led by the Alternative Investment division of Shepherd Kaplan Krochuk, LLC (SKK), a diversified Wealth and Asset Management firm located in Boston, Massachusetts.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech